Literature DB >> 8228282

Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.

V Ghetie1, E Swindell, J W Uhr, E S Vitetta.   

Abstract

A method for the preparation of immunotoxins (ITs) containing one and two molecules of deglycosylated ricin A chain (dgA) bound to each molecule of anti-human CD22 mouse IgG1 monoclonal antibody is described. The cross-linking of antibody and dgA molecules was accomplished with N-succinimidyl-oxycarbonyl-alpha-methyl-(2-pyridyldithio) toluene. The two ITs were purified by successive chromatographies on Blue-Sepharose, Sephacryl S-200, Blue-Sepharose with NaCl gradient and Sephacryl S-300. The IT with two dgAs was seven-fold more cytotoxic to CD22+ Daudi cells than that containing one molecule of dgA.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8228282     DOI： 10.1016/0022-1759(93)90335-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


  3 in total

1.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

Review 2.  Chemical construction of immunotoxins.

Authors:  V Ghetie; E S Vitetta
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.860

3.  Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.

Authors:  D J Flavell; D A Boehm; A Noss; S U Flavell
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.